Second-line threapies of patients with early progression under CDK4/6-inhibitor in first-line. Data from the registry platform OPAL. 11. November 2022 Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. 2022. Annals of Oncology. 2022;33(232P):S643. Download SMARAGD: The prospective national clinical research platform to study characteristics, treatment and outcomes of patients with ovarian, fallopian tube, primary peritoneal and endometrial cancer in Germany. Decker T, Wöckel A, Juhasz-Böss I, Zaiss M, Nusch A, Gratzke K, u. a. 2022. Oncol Res Treat. 2022;45(suppl 2)(V273):72. Weiterlesen Routine care of early breast cancer (stage I-III) in germany. Data of the prospective, intersectoral research platform OPAL. Welt A, Zahn MO, Wöckel A, Stickeler E, Thoma M, Nusch A, u. a. 2022 Annals of Oncology. 2022;33(187P):S622. Download… Weiterlesen